CA2877941A1 - Compositions and methods for treating or preventing pneumovirus infection and associated diseases - Google Patents
Compositions and methods for treating or preventing pneumovirus infection and associated diseases Download PDFInfo
- Publication number
- CA2877941A1 CA2877941A1 CA2877941A CA2877941A CA2877941A1 CA 2877941 A1 CA2877941 A1 CA 2877941A1 CA 2877941 A CA2877941 A CA 2877941A CA 2877941 A CA2877941 A CA 2877941A CA 2877941 A1 CA2877941 A1 CA 2877941A1
- Authority
- CA
- Canada
- Prior art keywords
- mdt
- crystal form
- pattern
- diffraction peaks
- dihydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 201000010099 disease Diseases 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims description 105
- 208000004692 Pneumovirus Infections Diseases 0.000 title description 3
- BLUJRJMLDHEMRX-UHFFFAOYSA-N 2-[[2-hydroxy-5-[(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1N=Cc1ccc(O)c(c1)C(c1ccc(O)cc1)c1cc(C=Nn2nnnc2C)ccc1O BLUJRJMLDHEMRX-UHFFFAOYSA-N 0.000 claims abstract description 115
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 37
- 239000013078 crystal Substances 0.000 claims description 95
- -1 P-3 dihydrate Chemical class 0.000 claims description 58
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 13
- 241000711904 Pneumoviridae Species 0.000 claims description 12
- 241000711502 Paramyxovirinae Species 0.000 claims description 11
- 206010006448 Bronchiolitis Diseases 0.000 claims description 9
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 230000034994 death Effects 0.000 claims description 7
- 231100000517 death Toxicity 0.000 claims description 7
- 150000004683 dihydrates Chemical class 0.000 claims description 6
- 150000004682 monohydrates Chemical class 0.000 claims description 6
- 206010039083 rhinitis Diseases 0.000 claims description 5
- 206010033078 Otitis media Diseases 0.000 claims description 4
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 230000003434 inspiratory effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 40
- 229940079593 drug Drugs 0.000 abstract description 33
- 238000011282 treatment Methods 0.000 abstract description 27
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 12
- 239000002131 composite material Substances 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 77
- 239000008186 active pharmaceutical agent Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 239000000463 material Substances 0.000 description 37
- 239000000902 placebo Substances 0.000 description 36
- 229940068196 placebo Drugs 0.000 description 36
- 238000002425 crystallisation Methods 0.000 description 23
- 230000008025 crystallization Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 22
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 22
- 238000001144 powder X-ray diffraction data Methods 0.000 description 22
- 238000000634 powder X-ray diffraction Methods 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 239000000546 pharmaceutical excipient Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 238000009472 formulation Methods 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 238000001556 precipitation Methods 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 229960001375 lactose Drugs 0.000 description 14
- 239000008101 lactose Substances 0.000 description 14
- 230000001174 ascending effect Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 239000012296 anti-solvent Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000000113 differential scanning calorimetry Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- 208000006673 asthma Diseases 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000013125 spirometry Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 229940088679 drug related substance Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 230000009325 pulmonary function Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000711504 Paramyxoviridae Species 0.000 description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 6
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 229940008309 acetone / ethanol Drugs 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 229940126534 drug product Drugs 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 238000009533 lab test Methods 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- 238000002562 urinalysis Methods 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000008247 solid mixture Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000712079 Measles morbillivirus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000711386 Mumps virus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 238000002144 chemical decomposition reaction Methods 0.000 description 4
- 238000003795 desorption Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229960000329 ribavirin Drugs 0.000 description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010549 croup Diseases 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010011416 Croup infectious Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 231100001273 GLP toxicology study Toxicity 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000711920 Human orthopneumovirus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960000402 palivizumab Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000011170 pharmaceutical development Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000685566 Beilong virus Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241001506061 Cetacean morbillivirus Species 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000035314 Henipavirus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000756202 Pacific salmon paramyxovirus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000711899 Phocine morbillivirus Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940124679 RSV vaccine Drugs 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 108091006632 SLC13A3 Proteins 0.000 description 1
- 241000481302 Salmon aquaparamyxovirus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001678552 Tailam virus Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000009725 powder blending Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001812 pycnometry Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 244000000023 zoonotic pathogen Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666258P | 2012-06-29 | 2012-06-29 | |
| US61/666,258 | 2012-06-29 | ||
| PCT/US2013/048723 WO2014005098A2 (en) | 2012-06-29 | 2013-06-28 | Compositions and methods for treating or preventing pneumovirus infection and associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2877941A1 true CA2877941A1 (en) | 2014-01-03 |
Family
ID=49778754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2877941A Abandoned CA2877941A1 (en) | 2012-06-29 | 2013-06-28 | Compositions and methods for treating or preventing pneumovirus infection and associated diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9040569B2 (enExample) |
| EP (1) | EP2867216A4 (enExample) |
| JP (1) | JP2015524391A (enExample) |
| KR (1) | KR20150037946A (enExample) |
| CN (1) | CN104507918A (enExample) |
| AU (1) | AU2013282286A1 (enExample) |
| BR (1) | BR112014032290A2 (enExample) |
| CA (1) | CA2877941A1 (enExample) |
| EA (1) | EA201590124A1 (enExample) |
| HK (2) | HK1210163A1 (enExample) |
| IL (1) | IL236476A0 (enExample) |
| IN (1) | IN2014DN10680A (enExample) |
| MX (1) | MX2014015340A (enExample) |
| NZ (1) | NZ628880A (enExample) |
| TW (1) | TWI516283B (enExample) |
| WO (1) | WO2014005098A2 (enExample) |
| ZA (1) | ZA201409073B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015524391A (ja) | 2012-06-29 | 2015-08-24 | マイクロドース セラピューテクス，インコーポレイテッド | ニューモウイルス感染症および感染疾患を治療あるいは予防するための組成物および方法 |
| US10258620B2 (en) * | 2014-12-18 | 2019-04-16 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form |
| US20170151173A1 (en) * | 2015-11-30 | 2017-06-01 | Otic Pharma Inc. | Compositions and methods for otologic prophylaxis and treatment |
| WO2018071443A1 (en) | 2016-10-11 | 2018-04-19 | Microdose Therapeutx, Inc. | Inhaler and methods of use thereof |
| US20200085741A1 (en) * | 2018-09-14 | 2020-03-19 | Pharmosa Biopharm Inc. | Pharmaceutical composition for controlled release of weak acid drugs and uses thereof |
| CN109827875A (zh) * | 2019-04-10 | 2019-05-31 | 上海市食品药品检验所 | 一种用于测定吸入制剂溶出度的装置和方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495580B1 (en) * | 1998-01-29 | 2002-12-17 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| EP1051169A4 (en) * | 1998-01-29 | 2002-05-29 | Viropharma Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRAL INFECTIONS AND RELATED DISEASES |
| WO2002059132A1 (en) | 2001-01-26 | 2002-08-01 | Viropharma Incorporated | Intermediate compounds useful for making antiviral compounds |
| CA2495245A1 (en) | 2002-08-09 | 2004-02-19 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| CA2495266A1 (en) | 2002-08-09 | 2004-02-19 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| JP2015524391A (ja) | 2012-06-29 | 2015-08-24 | マイクロドース セラピューテクス，インコーポレイテッド | ニューモウイルス感染症および感染疾患を治療あるいは予防するための組成物および方法 |
-
2013
- 2013-06-28 JP JP2015520598A patent/JP2015524391A/ja not_active Withdrawn
- 2013-06-28 AU AU2013282286A patent/AU2013282286A1/en not_active Abandoned
- 2013-06-28 HK HK15110967.1A patent/HK1210163A1/xx unknown
- 2013-06-28 NZ NZ628880A patent/NZ628880A/en not_active IP Right Cessation
- 2013-06-28 WO PCT/US2013/048723 patent/WO2014005098A2/en not_active Ceased
- 2013-06-28 CA CA2877941A patent/CA2877941A1/en not_active Abandoned
- 2013-06-28 CN CN201380034589.0A patent/CN104507918A/zh active Pending
- 2013-06-28 HK HK15104634.7A patent/HK1203956A1/xx unknown
- 2013-06-28 KR KR20157002571A patent/KR20150037946A/ko not_active Withdrawn
- 2013-06-28 MX MX2014015340A patent/MX2014015340A/es unknown
- 2013-06-28 US US13/931,201 patent/US9040569B2/en not_active Expired - Fee Related
- 2013-06-28 EP EP13809282.0A patent/EP2867216A4/en not_active Withdrawn
- 2013-06-28 EA EA201590124A patent/EA201590124A1/ru unknown
- 2013-06-28 BR BR112014032290A patent/BR112014032290A2/pt not_active IP Right Cessation
- 2013-06-28 IN IN10680DEN2014 patent/IN2014DN10680A/en unknown
- 2013-07-01 TW TW102123484A patent/TWI516283B/zh not_active IP Right Cessation
-
2014
- 2014-12-10 ZA ZA2014/09073A patent/ZA201409073B/en unknown
- 2014-12-25 IL IL236476A patent/IL236476A0/en unknown
-
2015
- 2015-04-10 US US14/683,935 patent/US9504672B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA201590124A1 (ru) | 2015-06-30 |
| HK1203956A1 (en) | 2015-11-06 |
| MX2014015340A (es) | 2015-03-05 |
| JP2015524391A (ja) | 2015-08-24 |
| US9040569B2 (en) | 2015-05-26 |
| CN104507918A (zh) | 2015-04-08 |
| AU2013282286A1 (en) | 2015-01-22 |
| IN2014DN10680A (enExample) | 2015-08-28 |
| IL236476A0 (en) | 2015-02-26 |
| TW201416093A (zh) | 2014-05-01 |
| KR20150037946A (ko) | 2015-04-08 |
| EP2867216A4 (en) | 2015-12-09 |
| US20150209328A1 (en) | 2015-07-30 |
| TWI516283B (zh) | 2016-01-11 |
| US20140005239A1 (en) | 2014-01-02 |
| US9504672B2 (en) | 2016-11-29 |
| EP2867216A2 (en) | 2015-05-06 |
| NZ628880A (en) | 2016-08-26 |
| WO2014005098A2 (en) | 2014-01-03 |
| BR112014032290A2 (pt) | 2017-06-27 |
| HK1210163A1 (en) | 2016-04-15 |
| WO2014005098A3 (en) | 2014-02-27 |
| ZA201409073B (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9504672B2 (en) | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
| KR101473028B1 (ko) | 인플루엔자 치료제 | |
| US7446116B2 (en) | Montelukast amantadine salt | |
| BR112017005104B1 (pt) | Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
| JP2019048898A (ja) | インフルエンザウイルスの複製の阻害剤 | |
| CN104379130A (zh) | 曲尼司特组合物和共结晶体 | |
| JP7772899B2 (ja) | ニコチニルアルコールエーテル誘導体のマレイン酸塩、その結晶形、及びその使用 | |
| EP3652148B1 (en) | Amorphous form of vilanterol trifenatate and processes for the preparation thereof | |
| US20240238306A1 (en) | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a complication risk factor | |
| US20110256188A1 (en) | Dry powder pharmaceutical composition for inhalation | |
| CN115666510A (zh) | 用于治疗或预防病毒感染的氯法齐明组合物和方法 | |
| JP2007277228A (ja) | アンドラストの新規で安定な結晶構造体 | |
| CN121627718A (zh) | 化合物102d-6晶型及其制备方法 | |
| CN118290383A (zh) | 二氢杨梅素与吡啶甲酸共晶及制备方法和其药物组合物与用途 | |
| EA050044B1 (ru) | Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты | |
| HK40083799A (en) | Clofazimine composition and method for the treatment or prophylaxis of viral infections | |
| EA047921B1 (ru) | Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты | |
| CN118290385A (zh) | 染料木素与吡啶甲酸共晶及制备方法和其药物组合物与用途 | |
| CA2442608A1 (en) | Crystalline hydrochloride salt of (2r)-anti-5-(3-[-4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl)-2-hydroxypoxy}quinoline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141223 |
|
| FZDE | Discontinued |
Effective date: 20180403 |